Cargando…

Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis

BACKGROUND: Atopic dermatitis (AD) is a remitting relapsing chronic eczematous pruritic disease. Several studies suggest that gut microbiota may influence AD by immune system regulation. METHODS: We performed the first in‐human efficacy and safety assessment of fecal microbiota transplantation (FMT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mashiah, Jacob, Karady, Tal, Fliss‐Isakov, Naomi, Sprecher, Eli, Slodownik, Dan, Artzi, Ofir, Samuelov, Liat, Ellenbogen, Eran, Godneva, Anastasia, Segal, Eran, Maharshak, Nitsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926506/
https://www.ncbi.nlm.nih.gov/pubmed/34931478
http://dx.doi.org/10.1002/iid3.570
_version_ 1784670251739250688
author Mashiah, Jacob
Karady, Tal
Fliss‐Isakov, Naomi
Sprecher, Eli
Slodownik, Dan
Artzi, Ofir
Samuelov, Liat
Ellenbogen, Eran
Godneva, Anastasia
Segal, Eran
Maharshak, Nitsan
author_facet Mashiah, Jacob
Karady, Tal
Fliss‐Isakov, Naomi
Sprecher, Eli
Slodownik, Dan
Artzi, Ofir
Samuelov, Liat
Ellenbogen, Eran
Godneva, Anastasia
Segal, Eran
Maharshak, Nitsan
author_sort Mashiah, Jacob
collection PubMed
description BACKGROUND: Atopic dermatitis (AD) is a remitting relapsing chronic eczematous pruritic disease. Several studies suggest that gut microbiota may influence AD by immune system regulation. METHODS: We performed the first in‐human efficacy and safety assessment of fecal microbiota transplantation (FMT) for AD adult patients. All patients received 2 placebo transplantations followed by 4 FMTs each 2 weeks apart. AD severity and fecal microbiome profile were evaluated by the Scoring Atopic Dermatitis Score (SCORAD), the weekly frequency of topical corticosteroids usage, and gut microbiota metagenomic analysis, at the study beginning, before every FMT, and 1–8 months after the last FMT. RESULTS: Nine patients completed the study protocol. There was no significant change in the SCORAD score following the two placebo transplants. The average SCORAD score significantly decreased from baseline at Weeks 4–12 (before and 2 weeks after 4 times of FMT) (59.2 ± 34.9%, Wilcoxon p = .011), 50% and 75% decrease was achieved by 7 (77%) and 4 (44%) patients, respectively. At Week 18 (8 weeks after the last FMT) the average SCORAD score decreased from baseline at Week 4 (85.5 ± 8.4%, Wilcoxon p = .018), 50% and 75% decrease was achieved by 7 (77%) and 6 (66.7%) patients respectively. Weekly topical corticosteroids usage was diminished during the study and follow‐up period as well. Two patients had a quick relapse and were switched to a different treatment. Two patients developed exacerbations alleviated after an additional fifth FMT. Metagenomic analysis of the fecal microbiota of patients and donors showed bacterial strains transmission from donors to patients. No adverse events were recorded during the study and follow‐up period. CONCLUSIONS: FMT may be a safe and effective therapeutic intervention for AD patients, associated with transfer of specific microbial species from the donors to the patients. Further studies are required to reconfirm these results.
format Online
Article
Text
id pubmed-8926506
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89265062022-03-24 Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis Mashiah, Jacob Karady, Tal Fliss‐Isakov, Naomi Sprecher, Eli Slodownik, Dan Artzi, Ofir Samuelov, Liat Ellenbogen, Eran Godneva, Anastasia Segal, Eran Maharshak, Nitsan Immun Inflamm Dis Original Articles BACKGROUND: Atopic dermatitis (AD) is a remitting relapsing chronic eczematous pruritic disease. Several studies suggest that gut microbiota may influence AD by immune system regulation. METHODS: We performed the first in‐human efficacy and safety assessment of fecal microbiota transplantation (FMT) for AD adult patients. All patients received 2 placebo transplantations followed by 4 FMTs each 2 weeks apart. AD severity and fecal microbiome profile were evaluated by the Scoring Atopic Dermatitis Score (SCORAD), the weekly frequency of topical corticosteroids usage, and gut microbiota metagenomic analysis, at the study beginning, before every FMT, and 1–8 months after the last FMT. RESULTS: Nine patients completed the study protocol. There was no significant change in the SCORAD score following the two placebo transplants. The average SCORAD score significantly decreased from baseline at Weeks 4–12 (before and 2 weeks after 4 times of FMT) (59.2 ± 34.9%, Wilcoxon p = .011), 50% and 75% decrease was achieved by 7 (77%) and 4 (44%) patients, respectively. At Week 18 (8 weeks after the last FMT) the average SCORAD score decreased from baseline at Week 4 (85.5 ± 8.4%, Wilcoxon p = .018), 50% and 75% decrease was achieved by 7 (77%) and 6 (66.7%) patients respectively. Weekly topical corticosteroids usage was diminished during the study and follow‐up period as well. Two patients had a quick relapse and were switched to a different treatment. Two patients developed exacerbations alleviated after an additional fifth FMT. Metagenomic analysis of the fecal microbiota of patients and donors showed bacterial strains transmission from donors to patients. No adverse events were recorded during the study and follow‐up period. CONCLUSIONS: FMT may be a safe and effective therapeutic intervention for AD patients, associated with transfer of specific microbial species from the donors to the patients. Further studies are required to reconfirm these results. John Wiley and Sons Inc. 2021-12-20 /pmc/articles/PMC8926506/ /pubmed/34931478 http://dx.doi.org/10.1002/iid3.570 Text en © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Mashiah, Jacob
Karady, Tal
Fliss‐Isakov, Naomi
Sprecher, Eli
Slodownik, Dan
Artzi, Ofir
Samuelov, Liat
Ellenbogen, Eran
Godneva, Anastasia
Segal, Eran
Maharshak, Nitsan
Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title_full Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title_fullStr Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title_full_unstemmed Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title_short Clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
title_sort clinical efficacy of fecal microbial transplantation treatment in adults with moderate‐to‐severe atopic dermatitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926506/
https://www.ncbi.nlm.nih.gov/pubmed/34931478
http://dx.doi.org/10.1002/iid3.570
work_keys_str_mv AT mashiahjacob clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT karadytal clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT flissisakovnaomi clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT sprechereli clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT slodownikdan clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT artziofir clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT samuelovliat clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT ellenbogeneran clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT godnevaanastasia clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT segaleran clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis
AT maharshaknitsan clinicalefficacyoffecalmicrobialtransplantationtreatmentinadultswithmoderatetosevereatopicdermatitis